EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study

Michael H Tomasson iD, Shinsuke Iida, Ruben Niesvizky, Mohamad Mohty, Nizar J Bahlis, Joaquin Martinez-Lopez, Guenther Koehne, Paula Rodriguez-Otero iD, H Miles Prince, Andrea Viqueira, Eric Leip, Umberto Conte and 2 more

HemaSphere · 2024-07 · 8 (7)

DOI: 10.1002/hem3.136 ↗

At a glance

Journal article in HemaSphere, published online on 2024-07-24. Written by Michael H Tomasson and 13 co-authors. Institution: Department of Internal Medicine University of Iowa Iowa City Iowa USA. Cited 75 times so far (Crossref); 10 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NCI NIH HHS.

AbstractBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Intet abstract tilgængeligt.

Authors and institutions

  • Department of Internal Medicine University of Iowa Iowa City Iowa USA.
  • Department of Hematology & Oncology Nagoya City University Graduate School of Medical Sciences Nagoya Japan.
  • Multiple Myeloma Center New York-Presbyterian Hospital/Weill Cornell Medical Center New York New York USA.
  • Hematology and Cellular Therapy Department Sorbonne University, Hôpital Saint-Antoine and INSERM UMRS938 Paris France.
  • Division of Hematology and Bone Marrow Transplantation, Arnie Charbonneau Cancer Institute University of Calgary Calgary Alberta Canada.
  • Haematology and Haemotherapy Service Hospital Universitario 12 de Octubre, Complutense University of Madrid, Centro Nacional de Investigaciones Oncológicas, Instituto de Investigación Hospital 12 de Octubre Madrid Spain.

ORCID profiles: Michael H Tomasson, Paula Rodriguez-Otero

Funding

  • NCI NIH HHS

Cite

APA

Tomasson, M. H., Iida, S., Niesvizky, R., Mohty, M., Bahlis, N. J., Martinez-Lopez, J., Koehne, G., Rodriguez-Otero, P., Miles Prince, H., Viqueira, A., Leip, E., Conte, U., Sullivan, S. T., & Lesokhin, A. M. (2024). Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study. HemaSphere, 8(7). https://doi.org/10.1002/hem3.136

Vancouver

Tomasson MH, Iida S, Niesvizky R, Mohty M, Bahlis NJ, Martinez-Lopez J, et al. Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study. HemaSphere. 2024;8(7). doi:10.1002/hem3.136

BibTeX
@article{Tomasson2024,
  author = {Tomasson, Michael H and Iida, Shinsuke and Niesvizky, Ruben and Mohty, Mohamad and Bahlis, Nizar J and Martinez-Lopez, Joaquin and Koehne, Guenther and Rodriguez-Otero, Paula and Miles Prince, H and Viqueira, Andrea and Leip, Eric and Conte, Umberto and Sullivan, Sharon T and Lesokhin, Alexander M},
  title = {Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study},
  journal = {HemaSphere},
  year = {2024},
  volume = {8},
  number = {7},
  doi = {10.1002/hem3.136}
}
Start for free →